Insulin-like Growth Factor-1 and Its Receptor Mediate the Autocrine Proliferation of Human Ovarian Carcinoma Cell Lines
Overview
Authors
Affiliations
Background: IGF-1 regulates the growth of diverse mammalian cell types including several human carcinoma cell lines. The IGF-1 receptor is a glycosylated heterodimer which, upon binding with IGF-1, undergoes tyrosine autophosphorylation. The autophosphorylation of the beta-receptor subunit is a strict requirement for its mitogenic properties.
Experimental Design: In this study, we have assessed the role of the IGF-1 receptor in the proliferation of ovarian carcinoma cell lines in culture. Effects of anti-sense and sense oligodeoxynucleotides to IGF-1 receptor RNA were tested.
Results: The human ovarian carcinoma cell lines OVCAR-3 and CaOV-3 both grew autonomously in serum-free medium, and their growth was further stimulated by the addition of IGF-1. Incubation of cells with anti-sense oligodeoxynucleotides corresponding to the IGF-1 receptor RNA markedly inhibited cell proliferation both in serum-free medium and in the presence of IGF-1. The inhibition of cell growth by the oligodeoxynucleotides corresponded to a reduction in the amount of detectable phosphorylated IGF-1 receptor.
Conclusions: The findings indicate that IGF-1 and its specific receptor mediate the autocrine proliferation of human ovarian carcinoma cell lines.
IGF1R inhibition and PD-1 blockade improve anti-tumor immune response in epithelial ovarian cancer.
Somri-Gannam L, Meisel-Sharon S, Hantisteanu S, Bar-Noy T, Sigal E, Groisman G Front Oncol. 2024; 14:1410447.
PMID: 39450263 PMC: 11499063. DOI: 10.3389/fonc.2024.1410447.
Sun Y, Yin Z, Li S, Wu L, Zhang Y, Zhao Y Br J Cancer. 2024; 131(10):1683-1693.
PMID: 39369055 PMC: 11554678. DOI: 10.1038/s41416-024-02863-9.
Prospective Analysis of Circulating Biomarkers and Ovarian Cancer Risk in the UK Biobank.
Sasamoto N, Hathaway C, Townsend M, Terry K, Trabert B, Tworoger S Cancer Epidemiol Biomarkers Prev. 2024; 33(10):1347-1355.
PMID: 39007864 PMC: 11446659. DOI: 10.1158/1055-9965.EPI-24-0319.
Enhancing Immunotherapy in Ovarian Cancer: The Emerging Role of Metformin and Statins.
Almeida-Nunes D, Silvestre R, Dinis-Oliveira R, Ricardo S Int J Mol Sci. 2024; 25(1).
PMID: 38203494 PMC: 10779012. DOI: 10.3390/ijms25010323.
Kinase Inhibitors in the Treatment of Ovarian Cancer: Current State and Future Promises.
Skorda A, Bay M, Hautaniemi S, Lahtinen A, Kallunki T Cancers (Basel). 2022; 14(24).
PMID: 36551745 PMC: 9777107. DOI: 10.3390/cancers14246257.